Anthos Therapeutics Appoints Will Kane as President and Chief Commercial Officer and Venkat Ramanan as Chief Financial Officer
31. Oktober 2024 08:00 ET
|
Anthos Therapeutics
CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (“Anthos”), a transformative, clinical-stage biopharmaceutical company developing innovative therapeutic options for the...
Anthos Therapeutics Appoints Mia Kelley as General Counsel and Laurel Ostrom as Chief Human Resources Officer
10. Oktober 2024 08:00 ET
|
Anthos Therapeutics
CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (“Anthos”), a transformative, clinical-stage biopharmaceutical company developing innovative therapeutic options for the...
Anthos Therapeutics Announces ~84% of Eligible Patients Have Transitioned to Abelacimab in the AZALEA-TIMI 71 Extension Study of Atrial Fibrillation Patients at a Moderate-to-High Risk of Stroke
06. Juni 2024 08:15 ET
|
Anthos Therapeutics
75% of patients in the rivaroxaban arm voluntarily switched from the once-daily oral anticoagulant to once-monthly abelacimab Landmark AZALEA-TIMI 71 Study previously stopped early due to an...
Anthos Therapeutics Announces Appointment of Bill Meury as CEO
22. April 2024 11:09 ET
|
Anthos Therapeutics
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (Anthos), is a clinical-stage company developing innovative therapies for cardiovascular diseases, founded by...
Anthos Therapeutics Supported Global Survey of 3000+ Patients Prescribed Anticoagulants Detailing Impact of Patient-Relevant Bleeding (PRB) Presented at ISTH 2023
26. Juni 2023 07:00 ET
|
Anthos Therapeutics
Patient-Centric Survey Conducted in Collaborationwith StopAfib.org and the National Blood Clot Alliance Findings Suggest “Patient-Relevant Bleeding” More Accurate Than Current Terminology,...
Regulatory Authorities in China and Japan Approve Clinical Trials for Anthos Therapeutics’ Dual-Acting Factor XI/XIa Inhibitor Abelacimab
08. Juni 2023 11:10 ET
|
Anthos Therapeutics
Fewer than 26% of Chinese Patients with Atrial Fibrillation are Prescribed an Anticoagulant, while in Japan Almost One-Third of Patients are Undertreated Approximately 63% of Cancer Patients in China...
New Assessment Scale to Measure Adherence to Oral Anticoagulants Based on Impact of Patient Relevant Bleeding in Atrial Fibrillation Presented at ISPOR 2023
09. Mai 2023 09:45 ET
|
Anthos Therapeutics
Anticoagulant Bleeding Burden Adherence Confidence Assessment Scale [ABBA-CAS] Created to Better Address an Important Treatment Gap in the Management of Atrial Fibrillation (AF) and Bring Patient...
New Assessment Scale to Capture Patient Relevant Bleeding to be Presented at ISPOR 2023
05. Mai 2023 08:00 ET
|
Anthos Therapeutics
Additional presentation spotlights GARDENIA registry design in patientswith atrial fibrillation and atrial flutter Early Cost-Effectiveness Modeling for Patients with Atrial Fibrillation and Cancer...
First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation Deemed Unsuitable for Current Anticoagulants
03. Januar 2023 08:00 ET
|
Anthos Therapeutics
FDA Fast-Track designation was granted to investigate abelacimab for the prevention of stroke and systemic embolism in patients with atrial fibrillation LILAC-TIMI 76 trial is the third Phase 3...
Anthos Therapeutics Announces that Abelacimab Has Received FDA Fast Track Designation for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation
08. September 2022 08:00 ET
|
Anthos Therapeutics
This is the second Fast Track designation issued by the FDA for abelacimab Abelacimab is a dual-acting, once-monthly, fully human monoclonal antibody targeting both Factor XI and Factor XIa with high...